We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech for less than cash value

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: JamesK who wrote (679)10/29/2023 6:01:50 PM
From: A.J. Mullen1 Recommendation

Recommended By
Lance Bredvold

  Read Replies (1) of 683
Fate is interesting. I was tempted before the sell-off. It’s working on exciting stuff – off-the-shelf immunotherapies. At the beginning of the year, it chose to end rather than revise a collaboration with J&J which resulted in a termination fee to Fate of over $50m. They also announced a 50% reduction in headcount. It said it aimed to have a runway through 2025. Its cash is now approximately twice its current free-cash flow (including the termination fee).

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext